Reaction

Burns Second Degree reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,727 reports · 76 co-occurring drugs

As of the last recalculation, Burns Second Degree appears in 1,727 FAERS reports alongside 76 co-occurring drug terms. The strongest observed disproportionality signal is FELODIPINE EXTENDED-RELEASE TABLETS (PRR 178.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Felodipine Extended-Release Tablets	154	178.8	181.3
Felodipine	154	178.8	181.3
Fesoterodine Fumarate	139	168.0	170.2
Nitrofurantoin	126	99.3	100.0
Nitrofurantoin (Monohydrate/Macrocrystals)	126	98.0	98.7
Desoximetasone	109	73.5	73.9
Tofacitinib Citrate	76	73.0	73.5
Dapagliflozin	161	67.9	68.3
Tamsulosin Hydrochloride	87	54.1	54.3
Candesartan	134	49.0	49.2
Lisdexamfetamine Dimesylate	111	43.3	43.4
Adalimumab-Fkjp	149	42.3	42.5
Adalimumab-Aaty	149	41.4	41.6
Mesalamine	166	39.3	39.4
Latanoprost	147	38.4	38.5
Adalimumab-Adaz	149	37.1	37.3
Budesonide	161	36.2	36.3
Warfarin Sodium	120	33.4	33.5
Hydrocortisone Sodium Succinate	25	32.5	32.6
Esomeprazole	149	31.6	31.7
Anti-Itch	158	31.2	31.2
Anti-Pruritic	158	31.2	31.2
Antipruritic (Anti-Itch)	158	31.2	31.2
Cool Relief Gel With Aloe	158	31.2	31.2
Drs. Hydrocortisone	158	31.2	31.2
Hydrocortisone Continuous Spray	158	31.2	31.2
Hydrocortisone Spray	158	31.2	31.2
Anti-Itch Cream	158	31.2	31.2
Hydrocortisone Lotion	158	31.2	31.2
Hydrocortisone Cream 1%	158	31.1	31.2
Hydrocortisone Cream 1/2%	158	31.1	31.2
Hydrocortisone 1%	158	31.1	31.2
Hydrocortisone Cream	158	31.0	31.1
Escitslopram	136	30.5	30.6
Hydrocortisone Acetate	165	30.1	30.2
Escitalopram Oxalate	158	28.6	28.7
Sulfasalazine	163	27.6	27.7
Infliximab-Dyyb	64	27.4	27.4
Pravastatin Sodium	41	25.5	25.6
Adrenalinum	82	25.0	25.0
Vedolizumab	162	24.9	25.0
Empagliflozin	129	24.9	24.9
Hydrocortisone	163	24.2	24.2
Instalax Polyethylene Glycol 3350	24	23.6	23.7
Polyethylene Glycol 400	24	23.1	23.2
Candesartan Cilexetil	40	18.7	18.8
Ramipril	161	17.2	17.2
Epinephrine	85	16.4	16.4
Warfarin	157	16.3	16.3
Atorvastatin Calcium, Film Coated	90	16.3	16.3
Escitalopram	171	16.2	16.2
Levothyroxine Sodium Anhydrous	110	14.1	14.1
Bisoprolol Fumarate	145	14.0	14.0
Antacid	52	13.6	13.6
Doxepin	11	13.2	13.2
Citalopram Hydrobromide	109	13.0	13.0
Rosuvastatin Calcium	27	11.7	11.7
Oxycodone	161	11.3	11.4
Infliximab	180	11.0	11.0
Esomeprazole Magnesium Capsule, Delayed Release	13	10.9	10.9
Esomeprazole Magnesium Delayed Release Capsules	13	10.9	10.9
Esomeprazole Magnesium Dihydrate	13	10.8	10.8
Cortisone Acetate	11	10.8	10.8
Citalopram	113	10.6	10.6
Doxepin Hydrochloride	11	10.6	10.6
Rosuvastatin	156	10.0	10.0
Lansoprazole	133	9.7	9.7
Esomeprazole Magnesium	171	9.7	9.7
Voriconazole Injection	17	9.5	9.5
Tofacitinib	134	9.4	9.4
Amlodipine Besylate	100	8.7	8.7
Rivaroxaban	132	8.2	8.2
Voriconazole	18	7.2	7.2
Vemurafenib	4	4.0	4.0
Salicylic Acid	5	1.1	1.1
Adapalene	9	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.